Pharmacological Risks & Contraindications

Pharmacological Risks & Contraindications

Introduction to Pharmacological Assessment

An essential responsibility of the dental hygienist is the comprehensive evaluation of the patient's pharmacotherapeutic profile. Patients frequently take multiple prescription medications, over-the-counter drugs, and herbal supplements that directly impact dental hygiene care. The clinical assessment must identify drug actions, side effects, drug-drug interactions, and potential contraindications to dental materials or anesthetics. This knowledge allows the clinician to make critical treatment modifications, prevent systemic complications, and manage medication-related oral conditions.

Anticoagulant Therapy and Bleeding Risks

Anticoagulants are prescribed to prevent thromboembolic events in patients with cardiovascular conditions such as atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism, or mechanical prosthetic heart valves. Warfarin (Coumadin) is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver.

International Normalized Ratio (INR) Monitoring

To safely perform dental hygiene procedures on a patient taking warfarin, the clinician must review the patient's most recent International Normalized Ratio (INR). The INR is a standardized calculation that compensates for laboratory-specific variations in prothrombin time (PT) measurements.

• Normal Healthy Individual: An INR of approximately 1.0.
• Therapeutic Target Range: For most patients on warfarin (e.g., atrial fibrillation or DVT), the target INR is 2.0 to 3.0. For patients with mechanical heart valves, the target is higher, typically 2.5 to 3.5.
• Dental Hygiene Guidelines: Routine scaling, root planing, and other non-surgical periodontal procedures can be safely performed without altering the patient's warfarin regimen if the INR is ≤ 3.0 (some guidelines allow up to 3.5 for minor surgical interventions). Discontinuing or reducing warfarin prior to dental treatment is contraindicated because the risk of a life-threatening thromboembolic stroke far outweighs the risk of localized oral hemorrhage.
• INR > 3.5: If the INR is greater than 3.5, the patient is at a high risk for severe, uncontrolled hemorrhage. Dental hygiene care must be deferred, and the patient must be referred to their prescribing physician for coagulation management.
• Hemostasis Protocol: For any patient on anticoagulant therapy, the clinician must prepare local hemostatic agents prior to beginning treatment. These include sterile gauze for direct pressure, gelatin sponges (Gelfoam), oxidized regenerated cellulose (Surgicel), or a 4.8% tranexamic acid mouthwash rinse.
• Direct Oral Anticoagulants (DOACs): Medications such as apixaban (Eliquis), rivaroxaban (Xalto), and dabigatran (Pradaxa) directly inhibit clotting factors (such as Factor Xa or thrombin). These medications do not require routine INR monitoring, but clinicians must still utilize local hemostatic measures and monitor the patient for excessive bleeding.

Bisphosphonates and Medication-Related Osteonecrosis of the Jaw (MRONJ)

Bisphosphonates (e.g., alendronate [Fosamax], ibandronate [Boniva], zoledronic acid [Reclast]) are anti-resorptive medications that bind to bone mineral and inhibit osteoclast activity, thereby decreasing bone resorption and turnover. They are prescribed for osteoporosis, Paget's disease, and bone malignancies (e.g., multiple myeloma, bone metastases).

Pathophysiology of MRONJ

MRONJ is a severe adverse drug reaction characterized by areas of exposed, necrotic bone in the maxillofacial region that do not heal within 8 weeks in a patient with a history of anti-resorptive or anti-angiogenic therapy, and who has no history of radiation therapy to the craniofacial skeleton.

Route of Administration and Risk Factors

The risk of developing MRONJ is heavily dependent on the route of administration and duration of therapy:

• Intravenous (IV) Bisphosphonates: Commonly used in oncology to treat bone metastases (e.g., zoledronic acid). IV bisphosphonates carry a significantly higher risk of MRONJ (estimated at 1% to 10% of patients).
• Oral Bisphosphonates: Commonly prescribed for osteoporosis (e.g., alendronate). The risk of MRONJ is very low (estimated at < 0.1% to 0.2%), but the risk increases if the medication is taken for more than 3 to 4 years, or if the patient is also taking systemic corticosteroids.

Dental Hygiene Considerations

Before a patient initiates IV bisphosphonate therapy, a thorough dental exam and dental hygiene scaling should be completed to eliminate active periodontal infection, caries, and the need for future extractions. For patients already receiving bisphosphonates, elective invasive procedures that involve alveolar bone (e.g., extractions, periodontal surgery, dental implants) should be avoided. Non-surgical periodontal therapy is the preferred treatment approach. Meticulous plaque control and frequent maintenance visits are essential to prevent periodontal infections that could necessitate extractions, which are the primary trigger for MRONJ.

Cardiovascular Medications and Vasoconstrictor Limits

Cardiovascular medications frequently interact with local anesthetics and cause oral side effects.

Calcium Channel Blockers (CCBs)

CCBs, including nifedipine (Procardia), amlodipine (Norvasc), verapamil (Calan), and diltiazem (Cardizem), are used to treat hypertension, angina, and cardiac arrhythmias.

• Gingival Enlargement: CCBs inhibit calcium influx in gingival fibroblasts, leading to decreased collagenase activity and a subsequent accumulation of extracellular matrix proteins. Clinically, this manifests as a fibrous, firm, painless enlargement of the interdental papillae that can progress to cover the clinical crowns.
• Management: Meticulous plaque control and frequent professional scaling are critical, as plaque accumulation acts as a co-factor that worsens the inflammatory tissue response. In severe cases that compromise chewing or oral hygiene, a surgical gingivectomy may be necessary. However, the condition will recur if the patient remains on the medication, and a consultation with the physician to switch to a different drug class (e.g., ACE inhibitors or ARBs) is often recommended.

Beta-Blockers and Epinephrine Interactions

Beta-adrenergic blockers are used to treat hypertension, arrhythmias, and prevent secondary myocardial infarctions.

• Non-selective Beta-blockers: Medications like propranolol (Inderal) block both beta-1 (cardiac) and beta-2 (bronchial and vascular smooth muscle) receptors.
• The Unopposed Alpha-1 Effect: If a local anesthetic containing epinephrine is administered to a patient taking a non-selective beta-blocker, the epinephrine stimulates alpha-1 (vasoconstrictive) receptors and beta receptors. Because the beta-2 receptors are blocked by the medication, the vasodilating effect of epinephrine in skeletal muscle is lost. This results in unopposed alpha-1 vasoconstriction, leading to a dramatic spike in systemic peripheral resistance and blood pressure. The severe rise in blood pressure triggers a vagal reflex, resulting in a dangerous compensatory bradycardia (slow heart rate).
• Vasoconstrictor Epinephrine Limit: For patients taking non-selective beta-blockers, or those with significant cardiovascular disease, the maximum dose of epinephrine must be limited to the cardiac dose of 0.04 mg per appointment. This is equivalent to approximately:
  • 2 cartridges of local anesthetic containing 1:100,000 epinephrine (0.018 mg per cartridge, total 0.036 mg).
  • 4 cartridges of local anesthetic containing 1:200,000 epinephrine (0.009 mg per cartridge, total 0.036 mg).

Dental Allergies and Clinical Management

Allergic reactions to dental materials and pharmacotherapeutic agents require swift identification and strict avoidance protocols.

Latex Allergy

• Type I (Immediate): An IgE-mediated hypersensitivity reaction to natural rubber latex proteins. Symptoms can manifest within minutes and include urticaria, rhinorrhea, bronchospasm, angioedema, hypotension, and anaphylaxis.
• Type IV (Delayed): A cell-mediated contact dermatitis. Symptoms (localized rash, erythema, pruritus, vesicles) typically develop 24 to 48 hours after contact.
• Clinical Management: Patients with documented latex allergy must be scheduled as the first appointment of the day to minimize exposure to airborne latex proteins (which can bind to cornstarch powder in gloves). The treatment room must be completely latex-free, utilizing nitrile gloves, non-latex prophylaxis cups, non-latex dams, and latex-free anesthetic cartridge plungers.
• Cross-reacting Foods: Clinicians must be aware that patients allergic to latex often share cross-reactivity with certain fruits due to similar protein structures (latex-fruit syndrome). These include bananas, kiwis, avocados, chestnuts, and passion fruit.

Local Anesthetic Allergies

• Amides vs. Esters: Local anesthetics are divided into amides (e.g., lidocaine, mepivacaine, articaine, prilocaine) and esters (e.g., benzocaine, tetracaine, procaine).
• Allergenicity: True IgE-mediated allergic reactions to amide local anesthetics are extremely rare. Most reported allergic events are actually psychogenic (e.g., vasovagal syncope from injection anxiety), epinephrine sensitivity (palpitations, tachycardia), or mild systemic toxicity due to accidental intravascular injection.
• Ester Allergies: Ester anesthetics have a higher rate of allergenicity because they are metabolized to para-aminobenzoic acid (PABA), a known allergen. Amide anesthetics do not metabolize to PABA.
• Cross-reactivity: There is no cross-reactivity between the amide and ester families. If a patient is truly allergic to amides, they can be referred for allergy testing. If emergency anesthesia is required, local infiltration of 1% diphenhydramine (Benadryl) with 1:100,000 epinephrine can be used.

Penicillin Allergy

Penicillin is the most commonly reported drug allergy, though clinical testing shows that up to 90% of these patients do not actually have an IgE-mediated allergy. However, if a patient has a documented history of immediate hypersensitivity (hives, angioedema, anaphylaxis) to penicillin, alternative antibiotics must be selected for infective endocarditis prophylaxis or active dental infections.

• Alternatives: Recommended alternatives include cephalexin (2 g), azithromycin (500 mg), or clarithromycin (500 mg).
• Cross-reactivity Warning: Cephalosporins (such as cephalexin) should be avoided in patients with a history of penicillin-induced anaphylaxis due to a 1% to 10% risk of cross-reactivity, which is based on the similarity of their beta-lactam rings.